Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. 2017 National Survey on Drug Use and Health: Methodological Summary and Definitions. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. 2013.
   Google Scholar
• Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–288. doi:10.1016/j.neubiorev.2017.08.019
   PubMed Web of Science ®Google Scholar
• Geschwind DH, Flint J. Genetics and genomics of psychiatric disease. Science. 2015;349:1489–1494. doi:10.1126/science.aaa8954
   PubMed Web of Science ®Google Scholar
• Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. doi:10.1038/nrdp.2016.65
   PubMed Web of Science ®Google Scholar
• Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123–133. doi:10.4088/JCP.v64n0204
   PubMed Web of Science ®Google Scholar
• Conway CR, George MS, Sackheim HA. Toward an evidence-based, operational definition of treatment-resistant depression. When enough is enough. JAMA Psychiatry. 2017;74:9–10. doi:10.1001/jamapsychiatry.2016.2586
   PubMed Web of Science ®Google Scholar
• Giakoumatos CI, Osser D. The psychopharmacology algorithm project at the harvard south shore program: an update on unipolar nonpsychotic depression. Harv Rev Psychiatry. 2019;27(1):33–52. doi:10.1097/HRP.0000000000000197
   Web of Science ®Google Scholar
• Anderson IM. We all know what we mean by treatment-resistant depression - don’t we? Br J Psychiatry. 2018;212(5):259–261. doi:10.1192/bjp.2018.56
   Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–17.
   PubMedGoogle Scholar
• Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53(2):109–118. doi:10.1177/0004867418808585
   Web of Science ®Google Scholar
• Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57–66. doi:10.3949/ccjm.75.1.57
   PubMed Web of Science ®Google Scholar
• Williams LM, Debattista C, Duchemin AM, Schatzberg AF, Nemeroff CB. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression. Transl Psychiatry. 2016;6:e799. doi:10.1038/tp.2016.61
   PubMed Web of Science ®Google Scholar
• Salerian AJ, Altar CA. The prefrontal cortex influence over subcortical and limbic regions governs antidepressant response by N=H/(M+R). Psychiatry Res. 2012;204:1–12. doi:10.1016/j.pscychresns.2012.04.019
   Web of Science ®Google Scholar
• Greicius MD, Flores BH, Menon V, et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry. 2007;62:429–437. doi:10.1016/j.biopsych.2006.09.020
   PubMed Web of Science ®Google Scholar
• Thase ME, Schwartz TL. Choosing medications for treatment-resistant depression based on mechanism of action. J Clin Psychiatry. 2015;76:720–727. doi:10.4088/JCP.14052ah2c
   Web of Science ®Google Scholar
• Denton WH, Carmody TJ, Rush AJ, et al. Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. Psychol Med. 2010;40:415–424. doi:10.1017/S0033291709990535
   Web of Science ®Google Scholar
• Caraci F, Calabrese F, Molteni R, et al. International union of basic and clinical pharmacology CIV: the neurobiology of treatment-resistant depression: from antidepressant classifications to novel pharmacological targets. Pharmacol Rev. 2018;70(3):475–504. doi:10.1124/pr.117.014977
   Web of Science ®Google Scholar
• Nikkheslat N, McLaughlin AP, Hastings C, et al. Childhood trauma, HPA axis activity and antidepressant response in patients with depression. Brain Behav Immun. 2020;87:229–237. doi:10.1016/j.bbi.2019.11.024
   PubMed Web of Science ®Google Scholar
• Perrin AJ, Horowitz MA, Roelofs J, Zunszain PA, Pariante CM. Glucocorticoid resistance: is it a requisite for increased cytokine production in depression? A systematic review and meta-analysis. Front Psychiatry. 2019;10:423. doi:10.3389/fpsyt.2019.00423
   PubMed Web of Science ®Google Scholar
• Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31(3):628–636. doi:10.1038/sj.npp.1300884
   PubMed Web of Science ®Google Scholar
• Block T, Petrides G, Kushner H, Kalin N, Belanoff J, Schatzberg A. Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression. J Clin Psychopharmacol. 2017;37(5):505–511. doi:10.1097/JCP.0000000000000744
   Web of Science ®Google Scholar
• Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol. 2011;31(4):436–440. doi:10.1097/JCP.0b013e3182239191
   Web of Science ®Google Scholar
• Yuen EY, Liu W, Karatsoreos IN, et al. Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory. Mol Psychiatry. 2011;16(2):156–170. doi:10.1038/mp.2010.50
   PubMed Web of Science ®Google Scholar
• Anacker C, Cattaneo A, Musaelyan K, et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2013;110(21):8708–8713. doi:10.1073/pnas.1300886110
   PubMed Web of Science ®Google Scholar
• Murphy BE, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol. 1991;11:121–126.
   PubMed Web of Science ®Google Scholar
• O’Dwyer AM, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord. 1995;33:123–128. doi:10.1016/0165-0327(94)00082-K
   PubMed Web of Science ®Google Scholar
• Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Arch Gen Psychiatry. 2004;61:1235–1244. doi:10.1001/archpsyc.61.12.1235
   PubMed Web of Science ®Google Scholar
• de Kloet ER, Joels M, et al. Stress and the brain: from adaptation to disease. Nature Rev. 2005;6:6. doi:10.1038/nrn1683
   Web of Science ®Google Scholar
• Yau JL, Hibberd C, et al. The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats. Brain Res Mol Brain Res. 2002;106:117–123. doi:10.1016/S0169-328X(02)00418-7
   Google Scholar
• Otte C, Hinkelmann K, et al. Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res. 2010;44(6):339–346. doi:10.1016/j.jpsychires.2009.10.006
   PubMed Web of Science ®Google Scholar
• Lembke A, Gomez R, Tenakoon L, et al. The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 2013;38(1):115–121. doi:10.1016/j.psyneuen.2012.05.006
   Web of Science ®Google Scholar
• US Food and Drug Administration: FDA approved first treatment for post-partum depression. FDA news release; March 19, 2019. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression. Accessed January 27, 2021.
   Google Scholar
• Dichtel LE, Carpenter LL, Nyer M, et al. Low dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: an 8-week Randomized Placebo-controlled Study. Am J Psychiatry. 2020;177:965–973. doi:10.1176/appi.ajp.2020.19080844
   Web of Science ®Google Scholar
• Liu J, Clough SJ, Dubocovich ML. Role of the MT1 and MT2 melatonin receptors in mediating depressive‐ and anxiety‐like behaviors in C3H/HeN mice. Genes Brain Behav. 2017;16:546–553. doi:10.1111/gbb.12369
   Web of Science ®Google Scholar
• Valdés-Tovar M, Estrada-Reyes R, Solís-Chagoyán H, et al. Circadian modulation of neuroplasticity by melatonin: a target in the treatment of depression. Br J Pharmacol. 2018;175(16):3200–3208. doi:10.1111/bph.14197
   PubMed Web of Science ®Google Scholar
• Potměšil P. What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice? Ther Adv Psychopharmacol. 2019;9:2045125319855206. doi:10.1177/2045125319855206
   Web of Science ®Google Scholar
• Stuhec M, Oravecz R. Moclobemide as add-on therapy to agomelatine in a patient with treatment-resistant major depressive disorder: a psychopharmacological case. Wien Klin Wochenschr. 2016;128:295–298. doi:10.1007/s00508-015-0861-0
   Web of Science ®Google Scholar
• Suhs KW, Correll C, Eberlein CK, et al. Combination of agomelatine and bupropion for treatment-resistant depression: results from a chart review study including a matched control group. Brain Behav. 2015;5:e00318. doi:10.1002/brb3.318
   Web of Science ®Google Scholar
• Corruble E, de Bodinat C, Belaïdi C, Goodwin GM, agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16(10):2219–2234. doi:10.1017/S1461145713000679
   PubMed Web of Science ®Google Scholar
• Laux G, Huttner NA; VIVALDI study group. Subgroup analysis of the non-interventional study VIVALDI: agomelatine in treatment-naive patients, in combination therapy and after treatment switch. Int J Psychiatry Clin Pract. 2014;18:86–96. doi:10.3109/13651501.2014.892138
   Web of Science ®Google Scholar
• Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther. 2017;11:1815–1825. doi:10.2147/DDDT.S102500
   PubMed Web of Science ®Google Scholar
• Szarmach J, Cubała WJ, Włodarczyk A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019;31(Suppl 3):585–590.
   PubMedGoogle Scholar
• Włodarczyk A, Cubała WJ, Szarmach J, Małyszko A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression patients: focus on adverse effects on the central nervous system. Psychiatr Danub. 2019;31(Suppl 3):530–533.
   Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826.
   PubMed Web of Science ®Google Scholar
• Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139–148. doi:10.1001/jamapsychiatry.2017.3739
   PubMed Web of Science ®Google Scholar
• Zheng W, Cai DB, Xiang YQ, et al. Adjunctive intranasal esketamine for major depressive disorder: a systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63–70. doi:10.1016/j.jad.2020.01.002
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4):19r12889. doi:10.4088/JCP.19r12889
   PubMed Web of Science ®Google Scholar
• EMA 2019. Spravato® (esketamine) summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information.en.pdf. Accessed Jan 02, 2021.
   Google Scholar
• Garay RP, Zarate CA Jr, Charpeaud T, et al. Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother. 2017;17(6):593–609. doi:10.1080/14737175.2017.1283217
   PubMed Web of Science ®Google Scholar
• Moskal JR, Burgdorf JS, Stanton PK, et al. The Development of Rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2016;15:47–56. doi:10.2174/1570159X14666160321122703
   Web of Science ®Google Scholar
• Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25(1):131–147. doi:10.1038/s41380-019-0414-4
   PubMed Web of Science ®Google Scholar
• Park LT, Kadriu B, Gould TD, et al. A randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol. 2020;23(7):417–425. doi:10.1093/ijnp/pyaa025
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Diaz Granados N, Jolkovsky L, et al. A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012;32:551–557. doi:10.1097/JCP.0b013e31825d70d6
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74:257–264. doi:10.1016/j.biopsych.2012.10.019
   PubMed Web of Science ®Google Scholar
• Lauterbach EC. Treatment resistant depression with loss of antidepressant response: rapid-acting antidepressant action of dextromethorphan, a possible treatment bridging molecule. Psychopharmacol Bull. 2016;46(2):53–58.
   PubMedGoogle Scholar
• Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1–3):239–243. doi:10.1016/j.jad.2006.03.004
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16(3):501–506. doi:10.1017/S1461145712000910
   PubMed Web of Science ®Google Scholar
• Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology. 2010;35:2510–2520. doi:10.1038/npp.2010.116
   PubMed Web of Science ®Google Scholar
• Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37(1):137–162.
   PubMed Web of Science ®Google Scholar
• Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A. 2010;107(6):2669–2674. doi:10.1073/pnas.0910658107
   PubMed Web of Science ®Google Scholar
• Felger JC, Haroon E, Patel TA, et al. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry. 2020;25(6):1301–1311. doi:10.1038/s41380-018-0096-3
   PubMed Web of Science ®Google Scholar
• Chamberlain SR, Cavanagh J, de Boer P, et al. Treatment-resistant depression and peripheral C-reactive protein. Br J Psychiatry. 2019;214(1):11–19. doi:10.1192/bjp.2018.66
   PubMed Web of Science ®Google Scholar
• Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–1391. doi:10.1001/jamapsychiatry.2014.1611
   PubMed Web of Science ®Google Scholar
• Andrade C. Antidepressant augmentation with anti-inflammatory agents. J Clin Psychiatry. 2014;75(9):975–977. doi:10.4088/JCP.14f09432
   Web of Science ®Google Scholar
• Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31–41. doi:10.1001/2013.jamapsychiatry.4
   PubMed Web of Science ®Google Scholar
• Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018;23(2):335–343. doi:10.1038/mp.2016.167
   PubMed Web of Science ®Google Scholar
• Husain MI, Chaudhry IB, Husain N, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol. 2017;31(9):1166–1175. doi:10.1177/0269881117724352
   PubMed Web of Science ®Google Scholar
• Nutt D. Psychedelic drugs-a new era in psychiatry? Dialogues Clin Neurosci. 2019;21(2):139–147.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Roseman L, Bolstridge M, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187. doi:10.1038/s41598-017-13282-7
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399–408. doi:10.1007/s00213-017-4771-x
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes F, Barreto D, Onias H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655–663. doi:10.1017/S0033291718001356
   PubMed Web of Science ®Google Scholar
• Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020;411:116715. doi:10.1016/j.jns.2020.116715
   Web of Science ®Google Scholar
• Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017;20(12):1036–1046. doi:10.1093/ijnp/pyx056
   PubMed Web of Science ®Google Scholar
• Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636–41. doi:10.4088/JCP.12m08093
   PubMed Web of Science ®Google Scholar
• Hori H, Kunugi H. The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial. ScientificWorldJournal. 2012;2012:372474. doi:10.1100/2012/372474
   PubMed Web of Science ®Google Scholar
• Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005;50(6):357–360. doi:10.1177/070674370505000612
   PubMed Web of Science ®Google Scholar
• Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67:432–438. doi:10.1016/j.biopsych.2009.11.021
   PubMed Web of Science ®Google Scholar
• Guo W, Machado-Vieira R, Mathew S, et al. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Transl Psychiatry. 2018;8(1):280. doi:10.1038/s41398-018-0311-7
   Web of Science ®Google Scholar
• Sakurai H, Dording C, Yeung A, et al. Longer-term open-label study of adjunctive riluzole in treatment-resistant depression. J Affect Disord. 2019;258:102–108. doi:10.1016/j.jad.2019.06.065
   PubMed Web of Science ®Google Scholar
• Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep brain stimulation for treatment-resistant depression: an integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry. 2018;23(5):1094–1112. doi:10.1038/mp.2018.2
   PubMed Web of Science ®Google Scholar
• Dandekar MP, Saxena A, Scaini G, et al. Medial forebrain bundle deep brain stimulation reverses anhedonic-like behavior in a chronic model of depression: importance of BDNF and inflammatory cytokines. Mol Neurobiol. 2019;56(6):4364–4380. doi:10.1007/s12035-018-1381-5
   PubMed Web of Science ®Google Scholar
• Leggett LE, Soril LJ, Coward S, Lorenzetti DL, MacKean G, Clement FM. Repetitive transcranial magnetic stimulation for treatment-resistant depression in adult and youth populations: a systematic literature review and meta-analysis. Prim Care Companion CNS Disord. 2015;17(6). doi:10.4088/PCC.15r01807
   Google Scholar
• Somani A, Kar SK. Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far. Gen Psychiatr. 2019;32(4):e100074. doi:10.1136/gpsych-2019-100074
   Web of Science ®Google Scholar
• Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression. Neurotherapeutics. 2017;14(3):716–727. doi:10.1007/s13311-017-0537-8
   PubMed Web of Science ®Google Scholar
• Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013;6(4):631–640. doi:10.1016/j.brs.2012.09.013
   PubMed Web of Science ®Google Scholar
• Vlainić JV, Šuran J, Vlainić T, Vukorep AL. Probiotics as an adjuvant therapy in major depressive disorder. Curr Neuropharmacol. 2016;14(8):952–958. doi:10.2174/1570159X14666160526120928
   PubMed Web of Science ®Google Scholar
• Tarleton EK, Littenberg B. Magnesium intake and depression in adults. J Am Board Fam Med. 2015;28:249–256. doi:10.3122/jabfm.2015.02.140176
   Web of Science ®Google Scholar
• Whittle N, Li L, Chen W-Q, et al. Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids. 2011;40:1231–1248. doi:10.1007/s00726-010-0758-1
   PubMed Web of Science ®Google Scholar
• Deacon G, Kettle C, Hayes D, Dennis C, Tucci J. Omega 3 polyunsaturated fatty acids and the treatment of depression. Crit Rev Food Sci Nutr. 2017;57(1):212–223. doi:10.1080/10408398.2013.876959
   PubMed Web of Science ®Google Scholar
• Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: a meta-analysis. Transl Psychiatry. 2019;9(1):190. doi:10.1038/s41398-019-0515-5
   PubMed Web of Science ®Google Scholar
• Włodarczyk A, Cubała WJ, Wielewicka A. Ketogenic diet: a dietary modification as an anxiolytic approach? Nutrients. 2020;12(12):3822. doi:10.3390/nu12123822
   Google Scholar
• Mura G, Moro MF, Patten SB, Carta MG. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. CNS Spectr. 2014;19(6):496–508. doi:10.1017/S1092852913000953
   PubMed Web of Science ®Google Scholar
• Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. J Psychiatr Pract. 2013;19(3):204–212. doi:10.1097/01.pra.0000430504.16952.3e
   PubMed Web of Science ®Google Scholar
• Uebelacker LA, Tremont G, Gillette LT, et al. Adjunctive yoga v. health education for persistent major depression: a randomized controlled trial. Psychol Med. 2017;47(12):2130–2142. doi:10.1017/S0033291717000575
   PubMed Web of Science ®Google Scholar
• Saeed SA, Cunningham K, Bloch RM. Depression and anxiety disorders: benefits of exercise, yoga, and meditation. Am Fam Physician. 2019;99(10):620–627.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Tucker RP, Greene PA, et al. Mindfulness-based interventions for psychiatric disorders: a systematic review and meta-analysis. Clin Psychol Rev. 2018;59:52–60. doi:10.1016/j.cpr.2017.10.011
   PubMed Web of Science ®Google Scholar